martedì, 5 maggio 2026

Notizie Newsletter

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Bevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery. To evaluate neoadjuvant bevacizumab in a randomized phase II ...
Leggi tutto

22 luglio 2019 – Epatite C: aggiornamento del 22/07/2019 sui pazienti arruolati

23 luglio 2019 – Prossima scadenza presentazione domande Bando AIFA 2018

Statistics Show Increase in US Cancer Survivors

July 22, 2019 - The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer ...
Leggi tutto

FDA Updates Durvalumab NSCLC Label to Include OS Data

July 22, 2019 - The FDA has updated the label for durvalumab for patients with unresectable, stage III non–small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemoradiation to include overall survival (OS) data from ...
Leggi tutto

Neratinib Approved in Canada for Early-Stage HER2+ Breast Cancer

July 17, 2019 - Health Canada has approved neratinib for the extended adjuvant treatment of patients with early-stage, hormone receptor (HR)–positive, HER2-overexpressed/amplified breast cancer within 1 year after completing trastuzumab-based adjuvant therapy. The ...
Leggi tutto

Economic Burden of Cancer in the United States in 2015

July 15, 2019 - There were more than 8.7 million person-years of life lost and $94.4 billion in earnings lost due to cancer among people aged 16 to 84 in the United States in 2015. The calculation comes from a new report published by Islami et al in JAMA Oncology. Cancer ...
Leggi tutto

EMA takes note of the European Ombudsman’s decision on pre-submission activities

July 19, 2019 - EMA welcomes the European Ombudsman’s recognition of the value and need for scientific advice and her recommendations are in line with EMA’s ongoing initiatives to further increase transparency. Early interactions with medicine developers and ...
Leggi tutto

Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer

Compared with single-marker genetic testing (SMGT), multigene panel sequencing (MGPS) has the potential to identify more patients with cancer who could benefit from targeted therapies, but the effects on outcome and total cost of care are uncertain. Our goal was to estimate ...
Leggi tutto

Will That Pulmonary Nodule Become Cancerous? A Risk Prediction Model for Incident Lung Cancer

This prospective investigation derived a prediction model for identifying risk of incident lung cancer among patients with visible lung nodules identified on computed tomography (CT). Among 2,924 eligible patients referred for evaluation of a pulmonary nodule to the Stony ...
Leggi tutto